• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EVP & President Interventional Byrd Richard sold $105,570 worth of shares (459 units at $230.00), decreasing direct ownership by 6% to 6,952 units (SEC Form 4)

    3/19/25 1:55:31 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Byrd Richard

    (Last) (First) (Middle)
    BECTON, DICKINSON AND COMPANY
    1 BECTON DRIVE

    (Street)
    FRANKLIN LAKES NJ 07417

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BECTON DICKINSON & CO [ BDX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP & President Interventional
    3. Date of Earliest Transaction (Month/Day/Year)
    03/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/18/2025 S 459 D $230 6,952 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 11, 2024.
    Donna Kalazdy, by power of attorney for Richard Byrd 03/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    10/1/2024$255.00 → $275.00Neutral → Buy
    Citigroup
    More analyst ratings

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      2/10/25 5:03:18 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    SEC Filings

    See more
    • Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BECTON DICKINSON & CO (0000010795) (Filer)

      6/16/25 4:32:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Becton Dickinson and Company

      SD - BECTON DICKINSON & CO (0000010795) (Filer)

      5/28/25 6:05:23 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - BECTON DICKINSON & CO (0000010795) (Filer)

      5/2/25 4:34:41 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

      For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

      11/23/21 3:16:12 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

      For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

      7/23/21 4:06:11 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Becton Dickinson downgraded by Citigroup with a new price target

      Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

      5/22/25 8:18:13 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

      5/2/25 8:06:47 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Goldman with a new price target

      Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00

      5/2/25 8:06:36 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and Chief ISC Officer Shan David sold $199,608 worth of shares (1,166 units at $171.19), decreasing direct ownership by 20% to 4,575 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      6/2/25 6:44:56 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Jones Christopher Ian Montague

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:22:33 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Byington Carrie L

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:20:56 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

      FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership wi

      5/28/25 6:50:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      FRANKLIN LAKES, N.J., May 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 2:00 pm Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports

      5/27/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

      FRANKLIN LAKES, N.J., May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients. Key Takeaways: The studies, led by the Cancer and AMR Consortium, which includes BD (Becton, Dickinson and Company) (NYSE:BDX), the Union for International Cancer Control (UICC), and the AMR Action Fund, found AMR rates among ke

      5/21/25 6:38:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care